Advocates fighting for the lives of those with metastatic disease

When CJ Corneliussen-James retired from the Air Force in 2003 after 24 years she was a senior intelligence officer in the Defense Prisoner of War/Missing Personnel Office where she worked to resolve the casees of missing servicemen and women still unaccounted for from the Vietnam and first Gulf Wars.

A year later, Lt. Col. Corneliussen-James was diagnosed with stage 2 breast cancer, which metastasized to her lung in 2006. After surgery that removed one lobe of her lung, CJ has been No Evidence of Disease (NED), but she knows it's a matter of time before she will face cancer again.

When she discovered the existing arsenal against metastatic breast cancer (MBC) was significantly out of proportion to the loss of life, she took action. She went on the road with her message: 30% of women who are diagnosed with early stage breast cancer become metastatic, but only 2% of funds go to metastatic disease research.

To raise more funds for research, CJ and three friends from the metastatic support group she founded, created METAvivor in 2009. Since then the nonprofit with its volunteer board has raised and awarded more than $300,000 to researchers working on metastatic disease. In 2011 they began their 30% for 30% campaign -- advocating that 30% of all cancer research funds and 30% of support activities be devoted to MBC research.

CJ is one of the Alamo Breast Cancer Foundation advocates at this year's SABCS meeting. She and METAvivor vice president Kelly Lange are eagerly following the research at SABCS hoping to see new approaches to MBC.

Lange was diagnosed with Stage 1 breast cancer in 1995 at age 32. By 2000 she had multiple regional lymph nodes involved and skin metastasis on her neck. Lange, a "super responder" to Herceptin and has watched as the drug has literally eliminated the skin metastases on her neck.

"We fund grants that will ultimately transition metastatic disease from a terminal illness to a controlled illness with a good quality of life," CJ says. "We fund the start up ideas, the risky out-of-the-box ideas ... the ones that could make a significant difference. These research proposals don't stand a chance of geting picked up unless we do this."

She says that although the trials funded thus far have yielded positive results, they aren't afraid to fund trials that end up negative because that gets all the researchers off that track. The group works with a scientific advisory board of physicians and researchers and has become known as the only organization that exclusively funds metastatic research.

Lange says that since METAvivor is an all volunteer organization, they can put 100 % of fundraiser profit into research grants. "This allows us to maximize the amount of funds going into MBC research. We keep our organization afloat by applying for grants to sustain our operations."

If you want to get CJ riled just tell her how much progress has been made, which is something she often hears.

"It's just not true," she says. "Women and men with metastatic disease are still dying in large numbers and we need to fund the research that can change that fact."

For more information on to their webpage.

Talk about this article with other patients, caregivers, and advocates in the General Discussions CURE discussion group.
Special Feature
Share Your Art
Related Articles
BRCA Mutations May Cause Drug Resistance in Breast and Ovarian Cancer
There is a relationship between the genetics of BRCA1 and BRCA2 mutations and the risk of a patient with breast or ovarian cancer being resistant to platinum-based chemotherapy, according to recent research conducted at the Perelman School of Medicine at the University of Pennsylvania. The study’s senior author Katherine Nathanson, M.D., spoke with CURE about these findings.
Sarah Sciortino on Fertility and Sexuality in Younger Patients with Ovarian Cancer
Sarah Sciortino, MSW, LSW, Oncology Psychosocial Support Services Program Coordinator at University of Chicago Hospital, discusses the unique concerns that younger patients with ovarian cancer can face.
Caring With Confidence: Study Examines Caregiver Mastery and Patient Survival in GBM
A recent study found that the level of family caregiver mastery may have an effect on the survival of patients with glioblastoma.
Related Videos
Examining Quality of Life Issues for Patients With MPNs
Sandra Allen-Bard, MSN, ANCC, AOCNP, of Weill Cornell Medical Center, discusses the impact myeloproliferative neoplasms can have on patients' quality of life.
Elliott Winton on the Changing Landscape of MPN Treatment
Elliott Winton, M.D., researcher, physician and 2016 MPN Hero, discusses some of the drastic changes that happened over the past decade or so in the world of MPNs. 
Siddhartha Mukherjee on Increasing MPN Awareness
Siddhartha Mukherjee, M.D., Ph.D, an oncologist, researcher and Pulitzer Prize-winning science writer, discusses the increasing awareness about myeloproliferative neoplasms (MPNs).
//For side ad protocol